---
document_datetime: 2025-11-18 14:56:17
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/efavirenz-emtricitabine-tenofovir-disoproxil-mylan-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: efavirenz-emtricitabine-tenofovir-disoproxil-mylan-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 6.711763
conversion_datetime: 2025-12-24 20:23:18.771897
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

## Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency' s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessmenthistory'section.Forthe completeproduct lifecycleprocedures,you mayneedtoalsorefertoEPAR-Proceduralsteps taken andscientific informationafterauthorisation(archive).

| Applicationnumber   | Scope                       | Opinion/ Notification 1 issued on   | Commission Decision IssuedÂ²/ amendedon   | Product Information affected3   | Summary   |
|---------------------|-----------------------------|-------------------------------------|------------------------------------------|---------------------------------|-----------|
| VariationtypeIA/    | A.ADMINISTRATIVECHANGES-A.7 | 18/11/2025                          |                                          | Annex II and                    |           |

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000312907                     | Deletion ofmanufacturingsitesfor an active substance, intermediate or finished product, packaging site,manufacturerresponsiblefor batch release, site where batch control takes place,orsupplierofastartingmaterial, reagent orexcipient(when mentioned in the dossier)*-Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |            |     | PL   |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------|
| Variation type IA / EMA/VR/0000278919 | This was an application for a group of variations. A.ADMINISTRATIVE CHANGES -A.4 Change inthenameand/oraddressof:a manufacturer(includingwhererelevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, startingmaterial,reagentorintermediate usedinthemanufactureoftheactive substance (where specified in the technical dossier)where noPh.Eur.Certificate of Suitability is part of the approved dossier; or amanufacturer of anovelexcipient(where specified in the technical dossier) - Accepted A.ADMINISTRATIVECHANGES-A.4Change inthenameand/oraddressof:a manufacturer(including whererelevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, startingmaterial,reagentorintermediate usedinthemanufactureoftheactive | 23/06/2025 | N/A |      |

<div style=\"page-break-after: always\"></div>

|                                       | dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient(where specified in the technical dossier)-Accepted A.ADMINISTRATIVE CHANGES -A.4 Change in the name and/or address of: a manufacturer(includingwhererelevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, startingmaterial,reagentorintermediate usedinthemanufactureof the active substance(where specified in the technical dossier)where noPh.Eur.Certificate of Suitabilityispartoftheapproveddossier;or a manufacturer of a novel excipient(where specified in the technical dossier) - Accepted   |            |     |             |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------|
| Variation type II / EMA/VR/0000177462 | B.IACTIVE SUBSTANCE-B.I.zSubstantial updates to Mod.3.2.S or the ASMF- Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 27/03/2025 | N/A |             |
| Variation type II / EMA/VR/0000225000 | B.IACTIVESUBSTANCE-B.I.zSubstantial updates toMod.3.2.S or the ASMF- Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 06/02/2025 | N/A |             |
| Variation type II / EMA/VR/0000179367 | C.IHUMANANDVETERINARYMEDICINAL PRODUCTS-C.I.4 Change(s) in the Summary of Product Characteristics, LabellingorPackageLeafletduetonew                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 05/09/2024 |     | SmPC and PL |

<div style=\"page-break-after: always\"></div>

|                                          | quality, preclinical, clinical or pharmacovigilancedata-Accepted Updateofsections4.4 and4.8of theSmPC inordertoamendanexistingwarningon Boneeffectsand toadd'bonemineral density decreased'to the list of adverse drug reactions (ADRs) with frequency common, based on the PRAC conclusions from the PSUSA for Emtricitabine/Tenofovir disoproxil (PSUSA/1210/202304).ThePackageLeaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet.   |            |     |
|------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IA_IN / EMA/VR/0000175870 | C.I.3 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of humanmedicinalproducts intended to implementtheoutcomeofaprocedure concermingPSURorPASS,ortheoutcome of the assessment done by the competent authority under Articles 45 or 46 of Regulation1901/2006-C.1.3.a Implementation of wording agreed by the competent authority -Refused                                                                                                                                                    | 24/04/2024 | N/A |